Reslizumab subcutaneous (SC) vs placeboFEV1 · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 46 participantsHigh